What is 'Ozempic face' and is it real?
Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.
'Ozempic face' is a media-popularized term for the gaunt, hollow appearance some patients develop with significant rapid weight loss on GLP-1 medications. It's not Ozempic-specific or even GLP-1-specific — any rapid weight loss (bariatric surgery, severe diet) produces the same effect because facial fat pads shrink faster than skin can remodel. The 'face' specifically refers to loss of volume in the cheeks and under-eye area combined with looser skin. Prevention/mitigation strategies: slow the rate of weight loss (slower titration, lower maintenance dose), maintain adequate protein intake, hydrate, and consider building/maintaining muscle. Treatments range from cosmetic (dermal fillers, fat-transfer procedures, biostimulators) to behavioral (re-feeding when at a healthy weight to restore fat volume). The trade-off is personal — many patients prefer the face change to the prior weight, others find it bothersome enough to consider treatment.
Where to start
Licensed US telehealth services that handle this. We may earn a commission when you sign up. See disclosure.
Ro
from $145/mo- Best for insured patients
- Best for clinical oversight
Ro Body — branded GLP-1 weight care program
Hims
from $199/mo- Best for cash-pay
- Best for speed
Hims Weight Loss — compounded GLP-1 from $199/mo
Noom Med
from $179/mo- Best for coaching
- Best for maintenance
Noom Med — GLP-1 + behavioral psychology coaching
Drugs referenced
Related questions
How much weight can you lose on Wegovy?
In the STEP-1 trial, adults on Wegovy 2.4mg weekly plus lifestyle changes lost approximately 15% of body weight on average over 68 weeks, vs ~2.4% in the placebo group. About one-third of patients lost ≥20%. Real-world outcomes are typically somewhat lower than trial results because adherence, dose escalation pace, and lifestyle support vary. Most patients s